No CrossRef data available.
Article contents
Reply to: Letter to the Editor: Sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained?
Published online by Cambridge University Press: 23 January 2017
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Correspondence
- Information
- Copyright
- Copyright © Cambridge University Press 2017
References
Hallak, JE, Maia-de-Oliveira, JP, Abrao, J, Evora, PR, Zuardi, AW, Crippa, JA, Belmonte-de-Abreu, P, Baker, GB, Dursun, SM (2013). Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry
70, 668–676.CrossRefGoogle ScholarPubMed
Hartz, SM, Pato, CN, Medeiros, H, Cavazos-Rehg, P, Sobell, JL, Knowles, JA, Bierut, LJ, Pato, MT; Genomic Psychiatry Cohort Consortium (2014). Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry
71, 248–254.Google Scholar
Maia-de-Oliveira, JP, Baker, GB, Dursun, SM, Hallak, JE (2016). Letter to the Editor: Sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained?
Psychological Medicine. Published online 9 December 2016. doi:10.1017/S003329171600307X.Google Scholar
Stone, JM, Morrison, PD, Koychev, I, Gao, F, Reilly, TJ, Kolanko, M, Mohammadinasab, A, Kapur, S, McGuire, PK (2016). The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Psychological Medicine
46, 3443–3450.Google Scholar